Cidara Therapeutics (CDTX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

CDTX Stock Forecast


Cidara Therapeutics (CDTX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $57.50, with a high of $69.00 and a low of $46.00. This represents a -8.26% decline from the last price of $62.68.

- $14 $28 $42 $56 $70 High: $69 Avg: $57.5 Low: $46 Last Closed Price: $62.68

CDTX Stock Rating


Cidara Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 1 Strong Buy (9.09%), 10 Buy (90.91%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 10 1 Strong Sell Sell Hold Buy Strong Buy

CDTX Price Target Upside V Benchmarks


TypeNameUpside
StockCidara Therapeutics-8.26%
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends


1M3M12M
# Anlaysts135
Avg Price Target$69.00$62.33$49.00
Last Closing Price$62.68$62.68$62.68
Upside/Downside10.08%-0.56%-21.83%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2542---6
Jun, 2532---5
May, 2542---6
Apr, 2542---6
Mar, 2532---5
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 09, 2025Seamus FernandezGuggenheim$69.00$50.9635.40%10.08%
Jun 24, 2025Guggenheim$68.00$46.8445.18%8.49%
May 16, 2025Seamus FernandezGuggenheim$50.00$25.5096.08%-20.23%
Mar 12, 2025Roy BuchananJMP Securities$46.00$21.00119.05%-26.61%
Aug 14, 2024Ed ArceH.C. Wainwright$12.00$6.4386.63%-80.86%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Jun 24, 2025GuggenheimBuyBuyhold
Jun 24, 2025RBC CapitalOutperformOutperformhold
Jun 23, 2025H.C. WainwrightBuyBuyhold
May 23, 2025RBC CapitalOutperformOutperformhold
May 16, 2025GuggenheimBuyBuyhold
Mar 12, 2025CitigroupOutperforminitialise
Aug 14, 2024H.C. WainwrightBuyupgrade
May 12, 2022NeedhamBuyBuyhold

Financial Forecast


EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-34.83$-16.75$-8.53$-5.25$-26.82----
Avg Forecast$-30.90$-17.67$-8.33$-5.60$-24.17$-9.59$-9.50$-8.39$-4.60
High Forecast$-30.49$-17.43$-7.88$-5.60$-24.17$-9.59$-3.41$-3.06$-4.60
Low Forecast$-31.31$-17.90$-8.71$-5.60$-24.17$-9.59$-17.63$-17.31$-4.60
Surprise %12.72%-5.21%2.40%-6.25%10.96%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.07M$49.57M$64.29M$63.91M$1.27M----
Avg Forecast$18.53M$46.64M$64.69M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
High Forecast$18.72M$47.11M$66.96M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Low Forecast$18.35M$46.17M$61.97M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Surprise %-34.89%6.28%-0.62%6.07%-74.67%----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.37M$-43.91M$-29.80M$-22.93M$-170.29M----
Avg Forecast$-49.20M$-77.23M$-35.59M$-22.93M$-105.63M$-41.91M$-45.98M$-44.51M$-20.11M
High Forecast$-39.36M$-76.21M$-18.86M$-13.30M$-105.63M$-41.91M$-14.89M$-13.37M$-20.11M
Low Forecast$-59.04M$-78.24M$-52.32M$-32.57M$-105.63M$-41.91M$-77.07M$-75.65M$-20.11M
Surprise %47.10%-43.14%-16.27%-61.21%----

CDTX Forecast FAQ


Is Cidara Therapeutics stock a buy?

Cidara Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cidara Therapeutics is a favorable investment for most analysts.

What is Cidara Therapeutics's price target?

Cidara Therapeutics's price target, set by 11 Wall Street analysts, averages $57.5 over the next 12 months. The price target range spans from $46 at the low end to $69 at the high end, suggesting a potential -8.26% change from the previous closing price of $62.68.

How does Cidara Therapeutics stock forecast compare to its benchmarks?

Cidara Therapeutics's stock forecast shows a -8.26% downside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Cidara Therapeutics over the past three months?

  • July 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cidara Therapeutics’s EPS forecast?

Cidara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-9.59, marking a -64.24% decrease from the reported $-26.82 in 2024. Estimates for the following years are $-9.5 in 2026, $-8.39 in 2027, and $-4.6 in 2028.

What is Cidara Therapeutics’s revenue forecast?

Cidara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $53.59M, reflecting a 4102.86% increase from the reported $1.28M in 2024. The forecast for 2026 is $132.54M, followed by $10.83M for 2027, and $62.41M for 2028.

What is Cidara Therapeutics’s net income forecast?

Cidara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-41.907M, representing a -75.39% decrease from the reported $-170M in 2024. Projections indicate $-45.978M in 2026, $-44.51M in 2027, and $-20.108M in 2028.